ClinicalTrials.gg
Sign In
Enrolling by invitationNCT07056686Updated Nov 4, 2026

Early Detection of Breast Cancer Among Syrian Women

An observational study in Breast Cancer Detection, sponsored by Al-Hawash Private University. Enrolling by invitation at 1 site in Syria. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Al-Hawash Private University · Observational

Updated Nov 4, 2026Study completion movedEligibility revised+3 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The goal of this observational study is to evaluate breast cancer awareness, screening practices, and barriers to early detection among women in the middle region of Syria. The main questions it aims to answer are:

  1. What is the level of awareness among women in this region regarding breast cancer symptoms and risk factors?
  2. How do women practice breast self-examination and professional screenings?
  3. What barriers prevent women from seeking early detection and treatment?

Participants will complete a survey assessing their knowledge, behaviors, and challenges related to breast cancer screening. The findings will inform public health interventions to improve awareness and early detection practices.

02

Conditions studied

  • Breast Cancer Detection

Browse trials for

03

In context

Breast Neoplasms

14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Al-Hawash Private University is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Women in the middle range between 118 and 65 years old

Eligibility criteria

Women aged 18 and older residing in Syria's middle region.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • Diagnostic testMammogram

    Each patient will undergo a mammogram, which is used to detect early signs of cancer, such as tumors or calcifications, before symptoms appear.

06

What researchers measure

Primary outcomes

  1. Number of Participants with early signs of breast cancer

    Time frame: From Participant enrolment to the end of the study: 2 weeks

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2025 to primary completion in May 2025, 0 months.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2025 → Jul 2027, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2025
First posted
Jul 9, 2025
StartActual
May 17, 2025
Primary completionActual
May 31, 2025
CompletionEst.
Jul 30, 2027was Jul 2025
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Al-Hawash Private University · Homs, Syria
Show 1 removed
  • Al-Hawash Private University · Homs, Syria
Nov 4, 2026
Study completion
Jul 30, 2025→Jul 30, 2027
Nov 4, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedWomen aged 18 years and older residing in theSyria's middle region of Syria.
Nov 4, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameNumber of Participants with early signs of breast cancerFrom Participant enrolment to the end of the study at 2 weeks → From Participant enrolment to the end of the study: 2 weeks
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • Al-Hawash Private University · Homs, Syria
    Show 1 removed
    • Al-Hawash Private University · Homs, Syria
    Study completion Jul 30, 2025→Jul 30, 2027
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedWomen aged 18 years and older residing in theSyria's middle region of Syria.
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameNumber of Participants with early signs of breast cancerFrom Participant enrolment to the end of the study at 2 weeks → From Participant enrolment to the end of the study: 2 weeks
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07056686
Lead sponsor
Al-Hawash Private University
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
May 17, 2025
Primary completion
May 31, 2025
Completion
Jul 30, 2027 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Breast Neoplasms →

Other studies from this sponsor

Al-Hawash Private University

Start the discussion